Hematologic Malignancies
📧 Sign up to get email alerts when something new happens for Hematologic Malignancies.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-01-06Clinical Trial Update: Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells [Phase 1, Phase 2]
A Phase 1/Phase 2 study evaluating immune reconstitution monitoring and pneumococcal vaccination in patients treated with CAR-T cells has be…
-
CLINICAL_TRIALS withdrawal · 2025-05-02Clinical Trial Update: Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant [NA]
This clinical trial update indicates that the study evaluating a donor stem cell boost for patients with low blood cell counts after a donor…
-
CLINICAL_TRIALS withdrawal · 2025-04-08Clinical Trial Update: A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) [Phase 1, Phase 2]
A pediatric/young adult trial evaluating pembrolizumab with investigational agents for hematologic malignancies or solid tumors has been wit…
-
CLINICAL_TRIALS withdrawal · 2024-10-18Clinical Trial Update: TCR Alpha/Beta and CD19-deplete Haplo-HSCT [Phase 2]
A Phase 2 clinical trial evaluating TCR alpha/beta and CD19-depleted haploidentical hematopoietic stem cell transplantation in pediatric pat…
-
CLINICAL_TRIALS withdrawal · 2018-07-06Clinical Trial Update: Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies [Phase 1]
A Phase 1 trial evaluating haploidentical hematopoietic progenitor transplantation with selective in vitro depletion of allo-reactive lympho…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2017-12-02Clinical Trial Update: Treg Cells for AGVHD in Non-myeloablative UCB Transplant [Phase 2]
A Phase 2 clinical trial investigating regulatory T cells to prevent acute graft-versus-host disease in non-myeloablative umbilical cord blo…
-
CLINICAL_TRIALS withdrawal · 2016-08-31Clinical Trial Update: Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation [Phase 2]
Phase 2 clinical trial evaluating TXA127 to reduce acute graft-versus-host disease in patients undergoing double umbilical cord blood transp…
-
CLINICAL_TRIALS withdrawal · 2015-06-08Clinical Trial Update: CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation [Phase 1]
Phase 1 trial evaluating CD56+CD3- natural killer cells following allogeneic stem cell transplantation in hematologic malignancies has been …
-
CLINICAL_TRIALS withdrawal · 2015-04-17Clinical Trial Update: Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies [Phase 1]
A Phase 1 trial evaluating the AKT inhibitor GSK690693 in relapsed or refractory hematologic malignancies has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-12-23Clinical Trial Update: Reiki as a Complementary Therapy: A Pilot Study [NA]
A pilot trial evaluating Reiki as a complementary therapy for hematologic malignancies has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-09-19Clinical Trial Update: In-Vitro Studies in Depletion of Haplotype Mismatched Alloreactive T Cells
This withdrawal notice concerns an in vitro study on depletion of haplotype-mismatched alloreactive T cells in the hematologic malignancies …
-
CLINICAL_TRIALS withdrawal · 2011-04-08Clinical Trial Update: Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host [Phase 2]
A Phase 2 trial evaluating donor lymphocytes sensitized by host antigens was withdrawn. The sponsor was Hadassah Medical Organization.